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Abstract Anthrax is still an endemic disease in some countries in the world and
has become a re-emerging disease in western countries with recent intentional out-
break. The aim of this study was to review our clinical experience with cutaneous
anthrax cases. From the patient’s ﬁles, transmission of the diseases, clinical ﬁndings
and severity of infection, treatment and outcome of patients were recorded.
Twenty-two cases were diagnosed as cutaneous anthrax in the last 7 years. Of
these cases, 10 cases were severe form of cutaneous anthrax, 10 cases were mild
form and 2 cases were toxemic shock due to cutaneous anthrax. The incubation
period was between 1 and 17 days. The main clinical characteristics of the cases
with severe cutaneous anthrax were fever, hemorrhagic bullous lesions surrounded
by an extensive erythema and edema, and leukocytosis. Two cases with toxemic
shock had low systolic blood pressure, apathy and toxemic appearance, leukocytosis,
hypoalbuminemia & hyponatremia. Penicillin G was given in 15 cases, amoxicillin in
4 and other antibiotics in 3 cases for 3—10 days. Skin lesion left deep tissue scar in
4 cases and were grafted.
Physicians working in endemic areas and also in western countries should be aware
of all clinical forms of anthrax.
© 2010 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
.Ltd. All rights reserved This study was partly presented at Bacillus-ACT 2009: The
International Bacillus anthracis, B. cereus, and B. thuringiensis
Conference, an ASM Conference, August 30—September 3, 2009,
Santa Fe, New Mexico. Abstract number. 38 A.
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nthrax is usually a disease of herbivores and only
ncidentally infects humans. Humans almost always
cquire anthrax directly or indirectly from infected
nimals. The main route of transmission is con-
act with or inhalation of Bacillus anthracis spores.
uman cases may occur in an agricultural, an
ndustrial environment or as a deliberately caused
isease [1,2]. Although, this infection is a forgotten
isease in western countries, it is still endemic in
ome parts of the world such as the Middle East,
Sciences. Published by Elsevier Ltd. All rights reserved.
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entral Asia and African countries [1—4]. In the
eptember 11 attack in USA, 22 human anthrax (11
utaneous and 11 inhalation) developed [5,6]. Just
ecently, two reports appeared from United King-
om. Two inhalation anthrax cases (one in 2006
ther in 2008) in bango drummer who used imported
nimal hides were reported and lastly an anthrax
utbreak in drug users in Scotland was reported
7,8]. Anthrax has become a re-emerging disease
n western countries and we can say anthrax is a
lobal issue.
The disease occurs primarily in three forms:
utaneous, respiratory and gastrointestinal. Sep-
is and meningitis can rarely develop after the
ymphohematogenous spread of B. anthracis from
primary lesion. Cutaneous anthrax accounts for
5% of human cases globally. Data from pre-
ntibiotic and vaccine days indicated that 10—40%
f untreated cutaneous anthrax cases might be
xpected to result in death. With the treatment,
1% cases are fatal. The clinical picture varies from
ild to severe form. Cutaneous anthrax can be
elf-limiting, and lesions resolve without complica-
ions or scarring in 80—90% of cases with treatment.
xtensive edema and toxemic shock can be seen
s a rare and potentially life-threatening complica-
ion of cutaneous anthrax [1—3,9]. Human anthrax
s decreasing by year in endemic areas. Older physi-
ians are familiar with all clinical form of anthrax,
ut young physicians are not familiar with anthrax.
or this reason, anthrax shows clinical diagnostic
ifﬁculties not only in western countries but also in
ndemic countries.
The aim of this study was to reevaluate our diag-
osed cutaneous anthrax cases and there outcome.
. Materials and methods
edical records of Patient’s diagnosed with cuta-
eous anthrax between 2002 and 2008 were
eviewed and evaluated for infection source, lesion
ocalization, severity of infection, complications,
reatment and outcome at the Department of Infec-
ious Diseases, Erciyes University Hospital, Kayseri,
urkey. The diagnosis was based on the history
f an exposure to sick animals or animal prod-
cts, clinical ﬁndings compatible with cutaneous
nthrax, demonstration of gram-positive bacilli
rom a lesion, and/or isolation of B. anthracis from
he lesion. The samples for Gram stain and culture
ere taken from the vesicles ﬂuid or under the crust
f developed. Skin biopsy was not performed.
A detailed history, including the occupation of
he patient, exposure to a sick animal or animal
s
e
t
r99
roducts (such as slaughtering, butchering, chop-
ing meat, touching an animal’s raw skin), the time
etween a known exposure and the appearance of
rst lesion and antibiotic therapy received prior
o admission was obtained from the patients upon
ospital admission. Severity of the infection, lesion
ite, antibiotic treatment, duration of therapy, and
utcome were recorded. In patients, peripheral
lood count, blood biochemistry and chest X-ray
ere investigated routinely. Materials taken from
he lesion and blood samples were cultured on
heep blood agar and in an automated blood culture
ystem consecutively.
The patients were categorized into three groups
ccording to clinical ﬁndings: mild cutaneous
nthrax deﬁned as the presence of a cutaneous
esion (<4 cm in diameter) surrounded a narrow
rythema, but no systemic symptoms; severe cuta-
eous anthrax deﬁned by the presence of a large
utaneous lesion with bullous reaction and exten-
ive edema, and systemic symptoms including fever,
achycardia and tachypnea; toxemic shock deﬁned
y the presence of a cutaneous lesion, systemic
ymptoms including fever, tachycardia, tachypnea,
cute mental changes and hypotension (systolic
lood pressure <90mmHg) and negative blood cul-
ure [1,3]. Bacteremia, superinfection and other
rgan involvement were also recorded.
. Results
wenty-two cases were evaluated. The median age
as 44 (18—64). Seven out of 22 patients were
emale. Table 1 shows the characteristics and out-
ome of patients with cutaneous anthrax. Of these,
0 cases were diagnosed as mild form of cutaneous
nthrax, 11 as severe cutaneous anthrax and 2 tox-
mic shock (one had severe cutaneous reaction and
iagnosed as toxemic shock).
The clinical picture in mild cases was character-
zed by a typical cutaneous lesion less than 4 cm
n diameter and surrounded by an erythema and
ow grade fever in the cases (Fig. 1). Leukocyte
ount was also below than 104/mm3 in these cases.
he clinical presentation of a severe form of cuta-
eous anthrax in 11 cases was characterized with
ever, hemorrhagic bullous lesions surrounded by
n extensive erythema and edema and leukocytosis
leukocytes count was over 104/dl) (Figs. 2 and 3).
Clinical picture in 2 cases with toxemic
hock was characterized with apathy and tox-
mic appearance, hypothermia (body tempera-
ure < 36 ◦C), extensive cutaneous inﬂammatory
eaction with extensive edema, hypotension (sys-
100
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Table 1 Demographic and clinical characteristics of patients with cutaneous anthrax.
Patient no Age/gender Duration of
incubation
(days)
Source of
infection
Site of the
lesion
Severity of
infection
Gram staina Culturea Previous
antibiotic
use (days)
Antibiotic
therapy
and route
of adminis-
tration
Duration of
therapy
(days)
Outcome
1 64 Female 7 Touching
dead cattle
Right arm
and left
wrist
Severe
cutaneous
anthrax
Negative Negative Penicillin
G + ciproﬂoxacin
[1]
Penicillin G
(i tra-
venous)
10 Left deep
scar, skin
graft
2 30 Male 1 Carrying
raw skin
Anterior
neck
Toxemic
shock,extensive
edema
Positive Negative No Penicillin G
(intra-
venous)
7 S. aureus
bac-
teremia,
recovered
3 44 Male 3 Carrying
dead
animal
carcass
Right arm Severe
cutaneous
anthrax and
extensive
edema,
toxemic
shock
Negative Positive No Penicillin G
(intra-
venous)
5 Left deep
scar, skin
graft
4 33 Male 6 Handled ill
cattle
Right and
left arm
Severe
cutaneous
anthrax
Negative Negative Erythromycin
4 tablets
Penicillin G
(intra-
venous)
5 Left deep
tissue scar,
skin graft
5 33 Male 6 Slaughtered
and skinned
dying sheep
Left hand
and wrist
Severe
cutaneous
anthrax
Positive Negative Unknown Clindamycin
(intra-
venous)
5 Left deep
tissue scar,
skin graft
6 55 Female 6 Slaughtered
dying sheep
Left hand
ﬁnger
Mild
cutaneous
anthrax
Positive Negative One dose
penicillin G
Amoxicillin
(intra-
venous)
5 Recovered
7 18 Female 15 Slaughtered
dying sheep
Left
forearm
Mild
cutaneous
anthrax
Negative Negative Penicillin G
[1]
Amoxicillin
(oral)
3 Recovered
8 23 Male 12 Handled ill
sheep
Left
forearm
Mild
cutaneous
anthrax
Negative Positive No Amoxicillin
(oral)
5 Recovered
A
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9 33 Male 7 Skinned
dying sheep
Right hand
wrist
Mild
cutaneous
anthrax
Negative Negative Cephalexin
[2]
Procaine
penicillin
(intramus-
cular)
5 Recovered
10 35 Female 17 Slaughtered
and
handled ill
cattle
Right hand
ﬁrst ﬁnger
Mild
cutaneous
anthrax
Positive Negative No Penicillin G
(intra-
venous)
5 Recovered
11 21 Female 3 Slaughtered
and
handled ill
cattle
Right arm Mild
cutaneous
anthrax
Negative Negative +b Ciproﬂoxacin
(intra-
venous)
5 Recovered
12 27 Male 8 Handled
and skinned
dying sheep
Right arm Severe
cutaneous
anthrax
Negative Negative + Penicillin G
(intra-
venous)
5 Recovered
13 30 Female 4 Handled
dying cattle
Left wrist Severe
cutaneous
anthrax
Negative Negative No Penicillin G
(intra-
venous)
10 Recovered
14 19 Male 8 Handled ill
animals
Right hand Severe
cutaneous
anthrax
Negative Negative Unknown Penicillin G
(intra-
venous)
5 Recovered
15 52 Female 3 Handled
and skinned
dying sheep
Left hand
and ﬁnger
Mild
cutaneous
anthrax.
Negative Negative + Procain
penicillin
(intramus-
cular)
7 Recovered
16 48 Male 5 Handled
dying sheep
Left hand
and ﬁnger
Severe
cutaneous
anthrax
Negative Negative Unknown Penicillin G
(intra-
venous)
10 Recovered
17 30 Male 8 Handled
dying sheep
Left hand
wrist
Mild
cutaneous
anthrax
Negative Negative Unknown Doxycycline
(oral)
5 Recovered
18 39 Male 12 Handled ill
cattle
Right hand Mild
cutaneous
anthrax
Positive Positive No Penicillin G
(intra-
venous)
10 Recovered
19 40 Male ? Handled
and skinned
dying sheep
Right face Severe
cutaneous
anthrax
Positive Negative + Penicillin G
(intra-
venous)
10 Recovered
102 M. Doganay et al.
Ta
bl
e
1
(C
on
ti
nu
ed
)
Pa
ti
en
t
no
Ag
e/
ge
nd
er
D
ur
at
io
n
of
in
cu
ba
ti
on
(d
ay
s)
So
ur
ce
of
in
fe
ct
io
n
Si
te
of
th
e
le
si
on
Se
ve
ri
ty
of
in
fe
ct
io
n
G
ra
m
st
ai
na
Cu
lt
ur
ea
Pr
ev
io
us
an
ti
bi
ot
ic
us
e
(d
ay
s)
An
ti
bi
ot
ic
th
er
ap
y
an
d
ro
ut
e
of
ad
m
in
is
-
tr
at
io
n
D
ur
at
io
n
of
th
er
ap
y
(d
ay
s)
O
ut
co
m
e
20
23
M
al
e
?
H
an
dl
ed
dy
in
g
sh
ee
p
Ri
gh
t
fo
re
ar
m
Se
ve
re
cu
ta
ne
ou
s
an
th
ra
x
N
eg
at
iv
e
N
eg
at
iv
e
U
nk
no
w
n
Pe
ni
ci
lli
n
G
(i
nt
ra
-
ve
no
us
)
5
Re
co
ve
re
d
21
28
M
al
e
2
H
an
dl
ed
dy
in
g
ca
tt
le
Ri
gh
t
fo
re
ar
m
Se
ve
re
cu
ta
ne
ou
s
an
th
ra
x
N
eg
at
iv
e
N
eg
at
iv
e
U
nk
no
w
n
Pe
ni
ci
lli
n
G
(i
nt
ra
-
ve
no
us
)
10
Re
co
ve
re
d
22
24
M
al
e
5
H
an
dl
ed
dy
in
g
sh
ee
p
Ri
gh
t
ar
m
M
ild
cu
ta
ne
ou
s
an
th
ra
x
N
eg
at
iv
e
N
eg
at
iv
e
U
nk
no
w
n
Am
ox
ic
ill
in
(o
ra
l)
5
Re
co
ve
re
d
a
Th
e
sw
ab
s
fo
r
G
ra
m
st
ai
n
an
d
cu
lt
ur
e
w
er
e
ta
ke
n
fr
om
th
e
ve
si
cl
es
ﬂ
ui
d
or
un
de
r
th
e
cr
us
t
if
de
ve
lo
pe
d.
b
Th
es
e
pa
ti
en
ts
re
ce
iv
ed
or
al
an
ti
bi
ot
ic
s,
ho
w
ev
er
,
th
e
ty
pe
of
th
e
an
ti
bi
ot
ic
w
as
un
cl
ea
r.
F
c
ﬁ
t
n
t
i
i
n
s
w
I
m
a
c
d
c
a
t
i
c
a
s
o
i
b
c
t
4
A
o
b
u
s
i
nig. 1 Typical appearance of mild cutaneous anthrax
haracterized with central depressed, surrounded vesicle
lled hemorrhagic ﬂuid and erythema on the arm.
olic blood pressure < 90mmHg), leukocytosis with
eutrophilia (WBC> 25× 103/mm3), hemaconcen-
ration, hypoalbuminemia, hyponatremia and an
ncrease in AST and ALT levels.
In the therapy, intravenous antibiotic and ﬂuid
nfusion were given to 10 cases with severe cuta-
eous anthrax. Two cases diagnosed as toxemic
hock were administered an antibiotic together
ith ﬂuid infusion, albumin and vasoactive drugs.
ntravenous penicillin was given to13 cases, intra-
uscularly procaine penicillin to 2 cases, oral
moxicillin to 4 cases and other antibiotics in 3
ases (ciproﬂoxacin in 1, doxycycline in 1 and clin-
amycine in 1). Antibiotic therapy was given to
ases between 3 and 10 days (mean 5—7 days).
The lesions were healed with antibiotic ther-
py and the crust left no scarring in 18 cases but
he lesions left deep tissue necrosis and scarring
n 4 cases, and the wound was grafted in these
ases (of these, 3 were severe cutaneous anthrax
nd 1 was severe cutaneous anthrax and toxemic
hock). No deep organ involvement was seen in any
f the cases as a complication. No superinfection
n cutaneous lesion was seen but catheter related
acteremia due to Methicillin Sensitive Staphylo-
occus aureus (MSSA) was observed in 1 case with
oxemic shock. No death was observed.
. Discussion
lthough anthrax is well controlled in the devel-
ped countries, anthrax remains of a global concern
ecause B. anthracis spores can potentially be
sed as a biological weapon. On the other hand,
ome local anthrax outbreak has been recorded
n western countries. For example, a case of
aturally-acquired inhalation anthrax was reported
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Fig. 2 Case 2. (A) He carried raw cattle skin. A pruritic lesion appeared on the anterior neck, after then, an extensive
edema and erythema developed from the neck to anterior ch
of the lesion at the 8th day of disease. (B) 18th day of diseas
in London, 2008 and another case was recorded
in Scotland in 2006. Both cases were bongo drum-
mers/drummakers who used imported animal hides
[7]. As of 14 January 2010, a total of 14 con-
ﬁrmed cases of anthrax infection in Scotland were
reported and 7 of these died. All cases were heroin
user. Possible source of infection is said that heroin
is transported in animal skin [8]. In developed coun-
Fig. 3 Case 4. He handled cattle and 6 days later lesions
had appeared on the right and left arms. An extensive
edema and hemorrhagic bullae appeared on both arms.
Typical appearance of severe cutaneous anthrax.
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pest wall and both arms. The picture shows appearance
e. Resolution of edema and occurrence of crust.
ries, there is also an infection risk after contact
ith a commercial product prepared from inad-
quately treated wool or leather. Products made
rom contaminated hair (e.g. shaving brush, wool
oat), skins (e.g. drums, drumheads made from
nimal skin), and bone meal (e.g. fertilizer) may
ontinue to be sources of infection for many years
1,3].
Anthrax is an endemic zoonosis in Turkey, partic-
larly in the eastern part. The incidence of disease
n Turkey has been decreasing with economic and
ocial changes, strict animal vaccination programs
nd education of farmers [2,4]. According to the
eport of the Ministry of Health, 262 human cases
ere reported in 2007, 126 in 2008 and 132 in 2009
n Turkey. Most of the cases reported until today
ere cutaneous anthrax. Other clinical forms of
nthrax, such as sepsis, meningitis, throat anthrax
nd intestinal anthrax were also reported before
his study [2,10—14]. Anthrax occurs throughout the
ear in Turkey, but themajority of cases occur in the
ate summer and autumn which is the driest and
ottest season [2,4]. Main source of transmission
f the infection to human is generally thru con-
act with infected animal or contaminated animal
roducts (such as skin, wool and meat) in Turkey, as
resented cases in this paper.
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The incubation period has been noted between
1 and 19 days, usually 2—7 days [1—3,9].
The incubation period ranged between 1 and
17 days for our case-series. The incubation
period was 5 days (a range of 1—10 days) for
the 11 cutaneous anthrax cases that were
reported during ‘anthrax letter’ events in
October—November 2001 in the United States
of America [5].
A well-developed anthrax lesion can be easily
recognized by physicians familiar with the disease.
Unfortunately, few physicians are familiar with this
clinical picture nowadays. The lesions are gener-
ally seen on an exposed area of the body, mostly
on the face, neck, hands and wrist. Generally
cutaneous lesions are single, but sometimes two
or more lesions may be present [1—3,9—11,13].
In our cases, a single lesion was present in 18
patients and two lesions in 4 patients. Lesions
were localized in hands and arms in 20 cases,
on the neck in 1 case and on the face in 1
case.
Although the anthrax lesions were healed with
antibiotic therapy, and the crust left no scarring in
the mild cases, cutaneous lesions in severe cases
left deep tissue necrosis and scarring in 4 cases in
the 3rd week of disease. This eschar was removed
surgically and grafted at 4—6 weeks of the dis-
ease.
Anthrax lesion begins to resolve after days 7—10
of the disease. Resolution takes several weeks
and is not hastened by treatment. Time to res-
olution is dependent on the size, location and
severity of the lesion. The initial crust separates
several weeks after onset, with subsequent healing
by granulation. Sometimes, the separation of the
crust is delayed and the lesion may become sec-
ondarily infected. So, well-developed larger dried
eschars were removed surgically in 4 cases. The
most appropriate time for the skin grafting in these
cases seems to be 4—6 weeks after the disease
appears because inﬂammatory reaction and indura-
tion around the lesion is completely resolved during
this period.
Airway obstruction by compression on the
trachea from edematous swelling around neck,
toxemic shock due to massive edema, sepsis,
meningitis, temporal artery inﬂammation, deep
tissue necrosis and secondary infection, and
deep scar tissue were reported as complica-
tions in cases of cutaneous anthrax previously
[1—3,11,13]. In our clinical experience, only
3 cases, including the 2 cases in this paper
were diagnosed as toxemic shock due to mas-
sive edema. One case was reported before [14].
The main clinical and laboratory characteristics
a
oM. Doganay et al.
n two cases with toxemic shock are hypotension,
ow body temperature, tachycardia, tachypnea,
ental changes, leukocytosis with neutrophilia,
yponatremia, increase in the level of AST, ALT
nd glucose, and a decrease in albumin level.
he therapy may include volume replacement
ncluding fresh plasma and antibiotic administra-
ion. Corticosteroids and dopamine may be also
iven.
Penicillin G is still the drug of choice, and
oxycycline or ciproﬂoxacin are now accepted
s the best alternatives in the treatment of
aturally-occurring anthrax. In the World Health
rganization (WHO) Guidelines, intramuscular pro-
aine penicillin, oral amoxicillin or penicillin V are
ecommended for the treatment of mild uncom-
licated cases of cutaneous anthrax. Intravenous
enicillin G is recommended in cutaneous anthrax
ith extensive edema [1].
The appropriate duration of treatment is debat-
ble. B. anthracis cannot be isolated from
utaneous lesions 24—48 h after initiation of any
ntibiotic active against B. anthracis. Currently,
HO Guidelines is suggesting to continue antimi-
robial therapy for 3—5 days (may be 3—7 days) in
ncomplicated cutaneous anthrax although there is
o controlled clinical study about the duration of
reatment in cutaneous anthrax. Antibiotic treat-
ent does not affect the progress of the lesion or
ther toxin-related systemic damage, and it does
ot alter the evolutionary stages. However, early
reatment will limit the size of lesion. For this rea-
on, early diagnosis of cutaneous anthrax and early
nitiation of therapy are very important. In our opin-
on, the duration of therapy may be adequate for
—5 days in uncomplicated cutaneous anthrax.
As a summary, anthrax is an endemic diseases in
urkey as well as in some Middle East Countries.
t is also threaten disease for western countries.
ajority of cases are occurring in agricultural area.
ll clinical form can be seen but majority of cases
re cutaneous anthrax. Clinical presentation of
utaneous anthrax may be mild or severe, and
ometimes leads to severe complications such as
epsis, toxemic shock and other organ involvement.
hese clinical forms are a life-threatening com-
lications of cutaneous anthrax. Early supportive
reatment for these complications with appropriate
ntimicrobial therapy could be life-saving. Physi-
ians, working not only in an endemic area for
nthrax but also western countries, should be
ware of all clinical forms of anthrax.Funding
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